Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Free Cash Flow: 2020-2025

Historic Free Cash Flow for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -$5.6 million.

  • Insight Molecular Diagnostics' Free Cash Flow rose 1.16% to -$5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$23.9 million, marking a year-over-year decrease of 17.74%. This contributed to the annual value of -$21.2 million for FY2024, which is 10.07% up from last year.
  • According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Free Cash Flow is -$5.6 million, which was up 16.23% from -$6.6 million recorded in Q2 2025.
  • Over the past 5 years, Insight Molecular Diagnostics' Free Cash Flow peaked at -$3.2 million during Q3 2023, and registered a low of -$14.8 million during Q1 2022.
  • In the last 3 years, Insight Molecular Diagnostics' Free Cash Flow had a median value of -$5.6 million in 2024 and averaged -$5.7 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first spiked by 73.85% in 2023, then crashed by 75.26% in 2024.
  • Over the past 5 years, Insight Molecular Diagnostics' Free Cash Flow (Quarterly) stood at -$7.5 million in 2021, then crashed by 39.97% to -$10.4 million in 2022, then spiked by 55.14% to -$4.7 million in 2023, then decreased by 19.22% to -$5.6 million in 2024, then rose by 1.16% to -$5.6 million in 2025.
  • Its Free Cash Flow was -$5.6 million in Q3 2025, compared to -$6.6 million in Q2 2025 and -$6.2 million in Q1 2025.